Zaorsky N, et al. - via PICOS/PRISMA/MOOSE selection protocol utilization, investigators evaluated 508 patients to examine the correlation of increased biologically effective dose (BED) with stereotactic body radiation therapy (SBRT) with improved local control (LC) or toxicities in people with locally advanced pancreatic cancer in five countries where candidates obtained definitive SBRT for nonmetastatic disease. They observed clinically significant toxicity of <7%, and SBRT for pancreatic cancer resulted in LC rates of 60% to 83%. They also noted that increasing BED₁₀ beyond 70 Gy was not correlated to increased rates of 1-year LC/acute toxicity, and no association was recorded between increasing BED₃ beyond 100 Gy and increased rates of late toxicity.